Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_1
3
75%
Ph phase_2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

NCT04158687
completedphase_1

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

NCT03880253
completedphase_1

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

NCT03830463
completedphase_1

A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers

NCT03778320

Clinical Trials (4)

Showing 4 of 4 trials
NCT04158687Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

Completed
NCT03880253Phase 1

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

Completed
NCT03830463Phase 1

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

Completed
NCT03778320Phase 1

A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy Volunteers

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4